around-the-clock opioid therapy for an extended period of time. ZGNX closed Wednesday's trading 40.50% higher at $1.70. The stock further gained 4.71% in extended trading.
For this week's round of "Better Know a Stock," I'm going to take a closer look at Zogenix . What Zogenix does Zogenix is a pharmaceutical company focused on developing therapies to treat central nervous disorders and moderate-to …
Zogenix has already raised almost $200 million in equity and debt since it was founded in 2006, according to Xconomy. Its financiers include GE Capital, Oxford Finance and CIT Healthcare. The company’s stock would be traded on the …
Shares of Zogenix Inc. rose 5 cents, or 3.8 percent, to $1.44 in midday trading. The stock has fallen 31 percent over the last year.
He served as a Director of Zogenix, Inc from August 2006 to October 25 ... including 2001 in which he placed in all three categories of stock picking, earnings estimate accuracy, and 'home run' hitting. Mr. Zisson graduated, magna cum …
He also holds stock options in Neuralieve ... NeurAxon, Union Chimique Belge and Zogenix. S. D. Silberstein is on the advisory panel of and receives honoraria from, Allergan, Amgen, Capnia, Coherex Medical, GlaxoSmithKline, Iroko …
ZGNX) today announced that it presented three posters highlighting its proprietary DosePro ® Needle-free Delivery …
Zogenix Inc : Zogenix announces agreement to refinance debt, further increasing company's expected 2017 cash balance . Continues to expect its cash runway to extend through end of 2017. . Entered into an amendment to its existing term …
Judging by some recent events, the Zogenix executive team may want to reach for a painkiller. Over the past week, the drug maker suffered a pair of setbacks. First, Express Scripts, the nation’s largest pharmacy benefits manager, …
Are you ready for the cold dark days that come with Daylight Saving Time? Prepare for winter skin before turning your clock back on Sunday. The main ingredient in aspirin, salicin, is the oldest pain reliever in history, but it took time and …